Stada Group
Thomas Stoeckl has extensive work experience in supply chain management and trade activities. Thomas has held various leadership positions in reputable pharmaceutical companies such as STADA Group, PUREN Pharma GmbH & Co. KG, Actavis - eine Marke der Teva, and Alphamed Arzneimittel GmbH. In their most recent role as Head of Supply Chain Eastern Europe and Director at STADA Group, they were responsible for optimizing supply chain procedures and ensuring reliable delivery of medicines. Thomas also served as the Managing Director according to trade law in Austria, overseeing trade activities and compliance. Additionally, they have held roles such as Head of Supply Chain & Portfolio Management Austria, Teamlead Launch & Portfolio Management, and Head of Supply Chain and Customer Service in the Austrian market. Throughout their career, Thomas has demonstrated their expertise in supply chain management, portfolio management, and customer service.
Thomas Stoeckl completed their education in the following chronological order:
- From 2014 to 2016, they obtained a Master of Science (MSc) degree in Healthcare Management from Universität für Weiterbildung Krems.
- Following that, from 2016 to 2018, they pursued a Master of Business Administration (MBA) degree in Healthcare Management from Universität für Weiterbildung Krems.
- Lastly, from 2022 to 2024, Thomas attended WU Executive Academy to earn a Prof. Master of Business Administration degree with a specialization in Entrepreneurship & Innovation.
This person is not in any offices
Stada Group
14 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.